David Rind, ICER CMO
August 5, 2021 09:24 AM EDT
FDA+

ICER of­fers fi­nal ver­dict against Bio­gen's ad­u­canum­ab: No proof it works, clear prospect of harm, wild­ly over­priced

John Carroll

Editor & Founder

The folks at ICER have crunched the da­ta on ad­u­canum­ab. The in­de­pen­dent drug watch­dog brought to­geth­er a pan­el of Alzheimer’s ex­perts to re­view the tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times